Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond
The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Neuroprotective drugs tested in clinical trials, particularly those that block N-methyl-D-aspartate-sensitive glutamate receptors (NMDARs), have failed miserably in large part because of intolerable side effects. However, one such drug, memantine, was recently approved by the European Union and the US FDA for the treatment of dementia following our group's discovery of its clinically tolerated mechanism of action. Here, we review the molecular basis for memantine efficacy in neurological diseases that are mediated, at least in part, by overactivation of NMDARs, producing excessive Ca(2+) influx through the receptor's associated ion channel and consequent free-radical formation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The discrepancy in ketamine IC50 values between these two studies might be explained by the concentration of agonist used (50 μM versus 1 mM glutamate), as higher agonist concentrations allow non-competitive antagonists, e.g. ketamine, to block more effectively due to a greater number of open channels”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Lipton, 2006
Citations
Cites
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972 · cited 1×
“D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK293 and N1E-115 cell systems in a non-competitive manner.”
BackgroundAlzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Magnesium gates glutamate-activated channels in mouse central neurones
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A., & Prochiantz, A. (1984) · Nature · doi:10.1038/307462a0 · Cited by 4,043
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139 · cited 1×
“The NR2 family of NMDAR subunits contains a binding site for glutamate, the endogenous agonist, whereas the NR1 subunit binds glycin”
BackgroundVoltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones
Mayer, M. L., Westbrook, G. L., & Guthrie, P. B. (1984) · Nature · doi:10.1038/309261a0 · Cited by 2,893
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,658 · cited 1×
“kon Channel + MEM ↔ Channel–MEM (Blocked channel) (1)”
Self-citationMolecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543
Heteromeric NMDA receptors: molecular and functional distinction of subtypes
Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., & Seeburg, P. H. (1992) · Science · doi:10.1126/science.256.5060.1217 · Cited by 2,541
Lipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., & Stamler, J. S. (1993) · Nature · doi:10.1038/364626a0 · Cited by 2,433
Self-citationNitric oxide mediates glutamate neurotoxicity in primary cortical cultures.
Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S., & Snyder, S. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.14.6368 · Cited by 2,174
Research works printed but not linked: 5
- Chen, H. -S. V. & Lipton, S. A. in Post Genomic Drug Discovery Research (ed. Huang, Z.) (John Wiley & Sons, Hoboken, NJ (in the press).
- Navia, B. A., Yiannoutsos, C., Ellis, R., Schifitto, G., Nath, A., Shriver, S., Millar, L. & Lipton, S. A. Memantine may prevent further cognitive decline in subjects with AIDS Dementia Complex with detectable CSF HIV RNA. Neurology 64 (Suppl. 1), A247–A238 (2005).
- Lipton, S. A., Rayudu, P. V., Choi, Y. -B., Sucher, N. J. & Chen, H. -S. V. in Prog Brain Res. (eds Mize, V., Dawson, T. M., Dawson, M. & Friedlander, M.) 73–82 (Elsevier, Amsterdam, 1998).
- Káradóttir, R., Cavelier, P., Bergersen, L. H. & Atwell, D. NMDA receptors in oligodendrocyte physiology and pathology. Nature (in the press).
- Micu, I. et al. NMDA receptors mediate Ca accumulation in central nervous system myelin during chemical ischemia. Nature (in the press).
Cited by
Items 201–300 of 943
Chen, B., Wang, G., Li, W., Liu, W., Lin, R., Tao, J., Jiang, M., Chen, L., & Wang, Y. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.12.028 · Cited by 71
An Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?
Sciaccaluga, M., Megaro, A., Bellomo, G., Ruffolo, G., Romoli, M., Palma, E., & Costa, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115991 · Cited by 70
Giron, L. B., Peluso, M. J., Ding, J., Kenny, G., Zilberstein, N., Koshy, J., Hong, K. Y., Rasmussen, H. E., Miller, G. E., Bishehsari, F., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160989 · Cited by 79
Novel mechanisms of central nervous system damage in HIV infection
Eugenin, E. (2010) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s9186 · Cited by 71
Apelin, a promising target for Alzheimer disease prevention and treatment
Masoumi, J., Abbasloui, M., Parvan, R., Mohammadnejad, D., Pavon-Djavid, G., Barzegari, A., & Abdolalizadeh, J. (2018) · Neuropeptides · doi:10.1016/j.npep.2018.05.008 · Cited by 72
Lipton, S. A., Gu, Z., & Nakamura, T. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(07)82001-0 · Cited by 80
Self-citationA New Target for Amyloid Beta Toxicity Validated by Standard and High-Throughput Electrophysiology
Varghese, K., Molnár, P., Das, M., Bhargava, N., Lambert, S., Kindy, M. S., & Hickman, J. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008643 · Cited by 69
“The initial increase in firing frequency we observed at all tested Ab concentrations could be due to an earlier reported direct depolarizing effect of Ab on the membrane potential or to the reputed ability of Ab to enhance glutamate-mediated excitotoxicity [41,42] by its action on NMDA receptors and consequently, thro…”
BackgroundPolycyclic Compounds: Ideal Drug Scaffolds for the Design of Multiple Mechanism Drugs?
der Schyf, C. J. V., & Geldenhuys, W. J. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.037 · Cited by 78
Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning
Kumar, V., Islam, A., Hassan, M. I., & Ahmad, F. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.06.017 · Cited by 71
Excitation/Inhibition Modulators in Autism Spectrum Disorder: Current Clinical Research
Canitano, R., & Palumbi, R. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.753274 · Cited by 78
Reprint of: Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs
Satoh, T., McKercher, S. R., & Lipton, S. A. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.11.002 · Cited by 72
Self-citationWhite matter synapses: Form, function, and dysfunction
Alix, J. J. P., & Domingues, A. M. D. J. (2011) · Neurology · doi:10.1212/wnl.0b013e3182088273 · Cited by 72
Alkhalifa, A. E., Alkhalifa, O., Durdanovic, I., Ibrahim, D. R., & Maragkou, S. (2025) · Journal of Dementia and Alzheimer's Disease · doi:10.3390/jdad2020017 · Cited by 66
Albensi, B. C. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207782341321 · Cited by 74
“ca NMDA drug targeting research has taken yet another turn and more recent reports with compounds such as memantine have demonstrated that there is still a strong rationale for blocking NMDA receptor activation, but that more clever approaches are necessary [22, 23].”
BackgroundDong, H., Yuede, C. M., Coughlan, C. A., Lewis, B. L., & Csernansky, J. G. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.53 · Cited by 73
Spitzer, S. O., Volbracht, K., Lundgaard, I., & Káradóttir, R. T. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.06.014 · Cited by 71
“Memantine trials for MS were terminated because of reversible neurological side effects (https://clinialtrials.gov/ct2/show/NCT00638833), but it is approved for Alzheimer’s disease where it is thought to protect neurons by preventing glutamate excitotoxicity (Lipton, 2006).”
BackgroundThe Implication of the Brain Insulin Receptor in Late Onset Alzheimer’s Disease Dementia
Folch, J., Ettcheto, M., Busquets, O., Sánchez-López, E., Castro-Torres, R., Verdaguer, E., Manzine, P., Poor, S., García, M., Olloquequi, J., et al. (2018) · Pharmaceuticals · doi:10.3390/ph11010011 · Cited by 63
Piccialli, I., Tedeschi, V., Caputo, L., Amato, G., De Martino, L., De Feo, V., Secondo, A., & Pannaccione, A. (2021) · Antioxidants · doi:10.3390/antiox10060937 · Cited by 64
“Only two classes of drugs, namely cholinesterase inhibitors and the N-methyl-D-aspartate (NMDA) receptor antagonist memantine, are currently included in AD therapy [10,11].”
BackgroundGalantamine potentiates the neuroprotective effect of memantine against NMDA‐induced excitotoxicity
Lopes, J. P., Tarozzo, G., Reggiani, A., Piomelli, D., & Cavalli, A. (2013) · Brain and Behavior · doi:10.1002/brb3.118 · Cited by 64
“Indeed, memantine shows a different pharmacological profile compared with other NMDAR antagonists (Lipton 2006).”
BackgroundInfluentialFrom tau to toxicity: Emerging roles of NMDA receptor in Alzheimer's disease
Chohan, M. O., & Iqbal, K. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-10112 · Cited by 73
“Although classically described as an un-competitive blocker of NMDAR-gated channels [34], the above studies provide additional mechanisms to explain its effectiveness.”
Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease
Takahashi, H., Xia, P., Cui, J., Talantova, M., Bodhinathan, K., Li, W., Saleem, S., Holland, E. A., Tong, G., Piña-Crespo, J., et al. (2015) · Scientific Reports · doi:10.1038/srep14781 · Cited by 63
Self-citationLuo, Y., Wang, Q., & Zhang, Y. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.12.011 · Cited by 65
“, 2010), is essential for the mediation of Ca2þ-dependent cell death (Lipton, 2006), and the excessive or inappropriate activity of this receptor contributes to”
BackgroundSaxena, S., & Hillis, A. E. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1373020 · Cited by 67
“It also has actions on serotonin and dopamine receptors, and it can diminish excitotoxicity [132,133].”
BackgroundKoukouli, F., & Maskos, U. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.018 · Cited by 69
Molokanova, E., Akhtar, M. W., Sanz-Blasco, S., Tu, S., Piña-Crespo, J. C., McKercher, S. R., & Lipton, S. A. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.2907-13.2014 · Cited by 62
“Here, we found that oligomeric A - induced potentiation of NO production in cortical neurons could be blocked by specific antagonists of calcium-permeable NMDARs, including memantine, a Food and Drug Administrationapproved drug for the treatment of AD (Parsons et al., 1999; Lipton, 2006).”
BackgroundSelf-citationA Novel NMDA Receptor Antagonist Protects against Cognitive Decline Presented by Senescent Mice
Companys-Alemany, J., Turcu, A. L., Bellver-Sanchis, A., Loza, M. I., Brea, J. M., Canudas, A. M., Leiva, R., Vázquez, S., Pallàs, M., & Griñán-Ferré, C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030284 · Cited by 64
“However, memantine has demonstrated specific effects because its low-affinity, uncompetitive antagonist performance, and can block the NMDAR over-activation without affecting its normal activation [46,47].”
BackgroundSwinney, D. C. (2008) · Pharmaceutical Medicine · doi:10.1007/bf03256679 · Cited by 79
Memantine in the treatment of mild-to-moderate Alzheimer’s disease
Cosman, K. M., Boyle, L. L., & Porsteinsson, A. P. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.2.203 · Cited by 70
Molecular Mechanism of Action (MMoA) in Drug Discovery
Swinney, D. C. (2011) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-386009-5.00009-6 · Cited by 85
Ginsenoside Rd Protects Neurons Against Glutamate-Induced Excitotoxicity by Inhibiting Ca2+ Influx
Zhang, C., Du, F., Shi, M., Ye, R., Cheng, H., Han, J., Ma, L., Cao, R. Y., Rao, Z., & Zhao, G. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9742-x · Cited by 62
Memantine Derivatives as Multitarget Agents in Alzheimer’s Disease
Marotta, G., Basagni, F., Rosini, M., & Minarini, A. (2020) · Molecules · doi:10.3390/molecules25174005 · Cited by 61
“contrast excitotoxicity while preserving glutamatergic synaptic functioning, possibly accounts for the clinical tolerability of the drug [7].”
BackgroundZaitsev, A. V., Kim, K. K., Vasilev, D. S., Lukomskaya, N. Y., Vv, L., Tumanova, N. L., Zhuravin, I. A., & Magazanik, L. G. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23500 · Cited by 61
“…NMDA receptor channel blocker memantine, which is approved for chronic clinical use in the treatment of Alzheimer’s disease (Parsons et al., 1999; Lipton, 2006), exerted anticonvulsant effects in maximal electroshock seizures (MES; Chojnacka-Wojcik et al., 1983; Urbanska et al., 1992; Parsons…”
BackgroundRodríguez-Muñoz, M., Cortés‐Montero, E., Pozo-Rodrigálvarez, A., Sánchez‐Blázquez, P., & Garzón-Niño, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6064 · Cited by 66
“Glutamate is the major excitatory neurotransmitter in the nervous system and deregulation of the NMDAR activity is associated with many neurological alterations, including neurodegenerative diseases [60], neuropathic pain [61, 62], mood disorders and psychosis/schizophrenia [63, 64].”
BackgroundDon't forget astrocytes when targeting Alzheimer's disease
Sadick, J. S., & Liddelow, S. A. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14568 · Cited by 57
“This overstimulation promotes excessive Ca2+ influx, resulting in free radical production, activation of proteolytic processes, and ultimately cell death (Lee et al., 2010; Lipton, 2006).”
BackgroundMolecular mechanisms of nitrosative stress-mediated protein misfolding in neurodegenerative diseases
Nakamura, T., & Lipton, S. A. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6525-0 · Cited by 67
Self-citationStazi, M., & Wirths, O. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02120-z · Cited by 59
Role of Receptors in Relation to Plaques and Tangles in Alzheimer’s Disease Pathology
Sharma, K., Pradhan, S., Duffy, L. K., Yeasmin, S., Bhattarai, N., & Schulte, M. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312987 · Cited by 60
“Upon ligand binding and subsequent receptor activation, the Mg2+ block is released, the channel opens and the influx of Ca2+, Na+ and K+ occurs inside the neuron [68,69].”
BackgroundHomeostatic Disinhibition in the Aging Brain and Alzheimer's Disease
Gleichmann, M., Chow, V. W., & Mattson, M. P. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101674 · Cited by 58
“Other hypotheses include prevention of excitotoxicity and prevention of NMDA receptor desensitization [72].”
Duerson, K., Woltjer, R. L., Mookherjee, P., Leverenz, J. B., Montine, T. J., Bird, T. D., Pow, D. V., Rauen, T., & Cook, D. G. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00186.x · Cited by 60
“However, the efficacy of the uncompetitive NMDA receptor antagonist, memantine, in treating AD hints at the plausibility of such an idea (36).”
BackgroundTayebati, S. K., Tullio, M. A. D., Tomassoni, D., & Amenta, F. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.02.349 · Cited by 59
“Glutamate contributes to amyloid betaprotein-induced cytotoxicity probably through over activation of Nmethyl-D-aspartate-sensitive (NMDA) glutamate receptor with consequent excessive Ca influx via the ion channel associated with this receptor, free-radical formation and neuronal injury [21].”
BackgroundEffects of memantine on the excitation-inhibition balance in prefrontal cortex
Povysheva, N. V., & Johnson, J. W. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.08.006 · Cited by 56
“Although memantine binds to a number of receptors, it is generally believed that the therapeutic effects of memantine are mainly associated with N-methyl-D-aspartate receptor (NMDAR) channel block (Lipton, 2006, Parsons et al., 2007, Johnson et al., 2015).”
BackgroundRosini, M., Simoni, E., Caporaso, R., Basagni, F., Catanzaro, M., Abu, I. F., Fagiani, F., Fusco, F., Masuzzo, S., Albani, D., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.011 · Cited by 56
“It is well known that memantine's primary amine plays a crucial role in receptor binding [13].”
BackgroundKervern, M., Angeli, A., Nicole, O., Léveillé, F., Parent, B., Villette, V., Buisson, A., & Dutar, P. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120394 · Cited by 63
“This conclusion is reinforced by the effects of memantine, which is thought to prevent the excessive or inappropriate activation of NMDARs while leaving physiological NMDAR-mediated transmission unaffected [41, 42].”
Galovic, M., Erlandsson, K., Fryer, T. D., Hong, Y. T., Manavaki, R., Sari, H., Chetcuti, S., Thomas, B. A., Fisher, M., Sephton, S. M., et al. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118194 · Cited by 60
“NMDA receptor blockrs have been used to treat seizures, Alzheimer’s disease or refracory depression ( Lipton, 2006 ; Murrough et al., 2013 ; Pellock et al., 006 ).”
MethodA role for polyamines in retinal ganglion cell excitotoxic death
Pernet, V., Bourgeois, P., & Polo, A. D. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04843.x · Cited by 56
“Glutamate excitotoxicity is thought to contribute to neuronal loss in stroke, cerebral ischemia, and chronic neurodegenerative diseases (Lipton and Rosenberg 1994; Chen and Lipton 2006).”
BackgroundPerlovich, G. L., Proshin, A. N., Volkova, Т. V., Petrova, L. N., & Бачурин, С. О. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300011r · Cited by 60
Optical control of AMPA receptors using a photoswitchable quinoxaline-2,3-dione antagonist
Barber, D. M., Liu, S.-A., Gottschling, K., Sumser, M., Hollmann, M., & Trauner, D. H. (2016) · Chemical Science · doi:10.1039/c6sc01621a · Cited by 58
Dong, Y., Kalueff, A. V., & Song, C. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.03.005 · Cited by 58
The Pharmacology of Visual Hallucinations in Synucleinopathies
Russo, M., Carrarini, C., Dono, F., Rispoli, M. G., Di Pietro, M., Di Stefano, V., Ferri, L., Bonanni, L., Sensi, S. L., & Onofrj, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01379 · Cited by 55
Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia
Kerchner, G. A., Tartaglia, M. C., & Boxer, A. L. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.6 · Cited by 59
Enantiomerically Pure 1,3-Dioxanes as Highly Selective NMDA and σ 1 Receptor Ligands
Köhler, J., Bergander, K., Fabian, J., Schepmann, D., & Wünsch, B. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301166m · Cited by 57
Wang, W., Jia, L., Luo, Y., Zhang, H., Cai, F., Mao, H., Xu, W., Fang, J., Peng, Z., Ma, Z., et al. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-9005-1 · Cited by 58
“Memantine is a partial antagonist of NMDA receptor, and has been reported to improve neurodegenerative diseases, such as Alzheimer's disease [25].”
Wei, H., Dobkin, C., Sheikh, A. M., Malik, M., Brown, W. T., & Li, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036981 · Cited by 55
“Studies have shown that memantine can be rapidly displaced from the NMDA receptor, which may avoid prolonged receptor blockade and the associated detrimental effects on learning and memory [13].”
Background2,4-Diketo esters: Crucial intermediates for drug discovery
Joksimović, N., Janković, N., Davidović, G., & Bugarčić, Z. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104343 · Cited by 56
Dysregulation of Neuronal Calcium Signaling via Store-Operated Channels in Huntington's Disease
Czeredys, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.611735 · Cited by 63
“The non-competitive NMDAR antagonist memantine (Lipton, 2006) protected YAC128 MSNs from glutamate-induced cell death.”
BackgroundNeuroprotective effect of memantine combined with topiramate in hypoxic–ischemic brain injury
Liu, C., Lin, N., Wu, B., & Qiu, Y. (2009) · Brain Research · doi:10.1016/j.brainres.2009.05.071 · Cited by 56
“In contrast to MK-801 and ketamine, memantine shows unusual clinical tolerance in the treatment of moderate-to-severe Alzheimer's disease in adults through its low affinity and relatively fast unblocking kinetics (de Lima et al., 2000; Lipton, 2004; Lipton, 2006).”
Wu, J., Tang, T.-S., & Борисович, Б. И. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.08.036 · Cited by 56
Sancheti, H., Patil, I., Kanamori, K., Brinton, R. D., Zhang, W., Lin, A.-L., & Cadenas, E. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.137 · Cited by 48
Protection from Glutamate-Induced Excitotoxicity by Memantine
Kutzing, M. K., Luo, V., & Firestein, B. L. (2011) · Annals of Biomedical Engineering · doi:10.1007/s10439-011-0494-z · Cited by 55
Martínez‐Coria, H., Arrieta-Cruz, I., Arrieta‐Cruz, I., & López-Valdés, H. E. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.293129 · Cited by 63
“…memantine being an uncompetitive, voltage dependent NMDA receptor antagonist with moderate affinity and fast on− off kinetics, one of its main therapeutic actions is it selectively blocks the pathological over-activation of the NMDA receptor in excitotoxicity (Parsons et al., 1999; Lipton, 2006).”
BackgroundThe psychopharmacology of autism spectrum disorder and Rett syndrome
Persico, A. M., Ricciardello, A., & Cucinotta, F. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00024-1 · Cited by 60
Movement Disorder in Ataxia-Telangiectasia
Nissenkorn, A., Hassin‐Baer, S., Lerman, S. F., Levi, Y. B., Tzadok, M., & Ben‐Zeev, B. (2012) · Journal of Child Neurology · doi:10.1177/0883073812441999 · Cited by 54
“Newer NMDA antagonists are extensively explored nowadays for their putative effect on preventing cell death and neurodegeneration.(31) Further studies on the role of amantadine, or the more potent NMDA receptor agonist memantine,(31) on degeneration of Purkinje cells in ataxia telangiectasia are warranted.”
BackgroundInfluentialNakamura, T., & Lipton, S. A. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402138 · Cited by 57
“mentia, multiple sclerosis, and ischemic brain injury, to name but a few.(1,2) Excessive activation of N-methyl-Daspartate (NMDA)-type glutamate receptors and subsequent Ca2þ influx at least in part mediates the toxicity evoked by the glutamate.”
BackgroundResultInfluentialSelf-citationVicente‐Sánchez, A., Sánchez‐Blázquez, P., Rodríguez-Muñoz, M., & Garzón, J. (2013) · Molecular Brain · doi:10.1186/1756-6606-6-42 · Cited by 54
“of NMDARs produces a series of perturbations that are associated with neurodegenerative diseases [36], mood disorders such as schizophrenia and depression [37,38], and neuropathic pain [39,40].”
BackgroundFranco, R., Rivas‐Santisteban, R., Casanovas, M., Lillo, A., Saura, C. A., & Navarro, G. (2020) · Cells · doi:10.3390/cells9051075 · Cited by 57
“Antagonists were: (5S,10R)-(+)-5-Methyl-10,11-dihydro-5H-dibenzo [a,d]cyclohepten-5,10-imine maleate (MK-801) and 2-(2-Furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e] [1,2,4]triazolo[1,5-c]pyrimidin-5-amine (SCH-58261).”
Redox regulation, protein S-nitrosylation, and synapse loss in Alzheimer’s and related dementias
Oh, C.-K., Nakamura, T., Zhang, X., & Lipton, S. A. (2024) · Neuron · doi:10.1016/j.neuron.2024.10.013 · Cited by 56
Self-citationTerminating Prolonged Refractory Status Epilepticus Using Ketamine
Hsieh, C., Sung, P., Tsai, J.-J., & Huang, C. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181d1e3cd · Cited by 52
Modulation of Glycine-Mediated Spinal Neurotransmission for the Treatment of Chronic Pain
Cioffi, C. L. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00956 · Cited by 62
The Na+/Ca2+exchanger in Alzheimer’s disease
Pannaccione, A., Piccialli, I., Secondo, A., Ciccone, R., Molinaro, P., Boscia, F., & Annunziato, L. (2020) · Cell Calcium · doi:10.1016/j.ceca.2020.102190 · Cited by 56
Scaffolding protein Homer1a protects against NMDA-induced neuronal injury
Wang, Y., Rao, W., Zhang, C., Zhang, C., Liu, M.-D., Han, F., Yao, L.-B., Han, H., Luo, P., Su, N., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.216 · Cited by 52
“Consistent with previous studies, we confirmed that NMDA treatment induced a large Ca influx, ROS generation and activation of downstream signaling pathways, all of which were related to NMDA-induced neuronal injury.(38) Homer1a regulation of calcium homeostasis and receptor trafficking has been reported in several ne…”
ResultThe glutamatergic system in Alzheimer’s disease: a systematic review with meta-analysis
Soares, C., Ros, L. U. D., Machado, L. S., da Rocha, A. S., Lazzarotto, G., Carello‐Collar, G., Bastiani, M. A. D., Ferrari‐Souza, J. P., Lussier, F. Z., Souza, D. O., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02473-0 · Cited by 52
“One should keep in mind that a systematic review with meta-analysis is a summary of the literature, which cannot completely eliminate the potential for bias or error since negative data have a higher probability of not being published.”
Caputo, L., Piccialli, I., Ciccone, R., de Caprariis, P., Massa, A., De Feo, V., & Pannaccione, A. (2021) · Phytotherapy Research · doi:10.1002/ptr.6827 · Cited by 49
“cal trials, only few drugs, such as cholinesterase inhibitors and the N-methyl-D-aspartate (NMDA) receptor antagonist memantine, revealed sufficient neuroprotective effects and are currently included in AD therapy (Francis, 2008; Lipton, 2006).”
BackgroundDe Felice, F., & Ferreira, S. (2006) · IUBMB Life (International Union of Biochemistry and Molecular Biology: Life) · doi:10.1080/15216540600702198 · Cited by 49
“Overactivation of NMDA receptors (by excessive glutamate or other agonists) leads to excitotoxic neuronal damage, involving increased intracellular calcium levels and increased mitrochondrial ROS production ( 16 ).”
BackgroundBanerjee, A., Schepmann, D., Köhler, J., Würthwein, E. ‐., & Wünsch, B. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.09.047 · Cited by 49
Antiapoptotic Drugs: A Therapautic Strategy for the Prevention of Neurodegenerative Diseases
X. Sureda, F., Junyent, F., Verdaguer, E., Auladell, C., Pelegri, C., Vilaplana, J., Folch, J., Maria Canudas, A., Beas Zarate, C., Pallas, M., et al. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795049732 · Cited by 49
“However, any beneficial effects are, at best, modest [10, 11].”
BackgroundŠpilovská, K., Korábečný, J., Šepsová, V., Jun, D., Hrabinová, M., Jošt, P., Múčková, Ľ., Soukup, O., Janočková, J., Kucera, T., et al. (2017) · Molecules · doi:10.3390/molecules22061006 · Cited by 50
Lee, S. Y., & Hur, S. J. (2019) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12451 · Cited by 50
New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis
Villoslada, P., & Steinman, L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1757647 · Cited by 55
“activation [109], it transiently deteriorates symptoms in patients with MS, reproducing pseudoexacerbations [110,111].”
BackgroundLysyl Oxidase Propeptide Inhibits FGF-2-induced Signaling and Proliferation of Osteoblasts
Vora, S. R., Palamakumbura, A. H., Mitsi, M., Guo, Y., Pischon, N., Nugent, M. A., & Trackman, P. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033597 · Cited by 47
Sułkowski, G., Dąbrowska‐Bouta, B., Chalimoniuk, M., & Strużyńska, L. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.05.006 · Cited by 51
“, 2005), which is a result of overstimulation of glutamate receptors, especially of the NMDA subtype (Lipton, 2006).”
InfluentialChidambaram, S. B., & Ramanathan, M. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.01.010 · Cited by 51
Amin, H., Nieus, T. R., Lonardoni, D., Maccione, A., & Berdondini, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-02635-x · Cited by 49
Wrighton, D. C., Baker, E. J., Chen, P. E., & Wyllie, D. J. A. (2008) · The Journal of Physiology · doi:10.1113/jphysiol.2007.143164 · Cited by 46
“The effects of memantine, another NMDAR channel blocker, used therapeutically in the treatment of dementia, have also been investigated (Parsons et al. 1993, 1999b; Chen & Lipton, 2005; Lipton, 2006).”
Regulation of membrane NMDA receptors by dynamics and protein interactions
Petit‐Pedrol, M., & Groc, L. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.202006101 · Cited by 50
“…major neurological and psychiatric disorders, such as Alzheimer’s, Huntington’s, and Parkinson’s diseases (Wenk, 2006; Bonuccelli and Del Dotto, 2006; Lipton, 2006; Fan and Raymond, 2007); schizophrenia (Kantrowitz and Javitt, 2012; Weinberger, 2019); depression (Maeng and Zarate, 2007);…”
BackgroundTreatment of post-stroke aphasia: A narrative review for stroke neurologists
Vitti, E., & Hillis, A. E. (2021) · International Journal of Stroke · doi:10.1177/17474930211017807 · Cited by 55
NMDA receptor activity regulates transcription of antioxidant pathways
Lipton, S. A. (2008) · Nature Neuroscience · doi:10.1038/nn0408-381 · Cited by 46
Self-citationAging of the Nmda Receptor: From A Mouse‘s Point of View
Magnusson, K. R. (2012) · Future Neurology · doi:10.2217/fnl.12.54 · Cited by 49
Counts, S., Perez, S. E., & Mufson, E. J. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8159-2 · Cited by 49
Jantas, D., Szymanska, M., Budziszewska, B., & Lasoń, W. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0370-6 · Cited by 48
“It is well recognized that memantine at low micromolar concentrations can antagonize extrasynaptic NMDA receptors more than synaptic ones [43, 44].”
BackgroundAnesthetic Sevoflurane Reduces Levels of Hippocalcin and Postsynaptic Density Protein 95
Zhang, J., Dong, Y., Zhou, C., Zhang, Y., & Xie, Z. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8746-1 · Cited by 45
“Memantine is a partial antagonist of NMDA receptor and can reduce influx of extracellular calcium [24].”
InfluentialMalaiya, M. K., Jain, A., Hurkat, P., Jain, A., & Jain, D. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.03.030 · Cited by 45
Pharmacologic neuroprotection in ischemic brain injury after cardiac arrest
Katz, A., Brosnahan, S. B., Papadopoulos, J., Parnia, S., & Lam, J. Q. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14613 · Cited by 47
Wise, L. E., & Lichtman, A. H. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.07.059 · Cited by 45
“One of memantine’s greatest benefits in AD, as well as in other neurodegenerative diseases, is believed to be its neuroprotective effects (Lipton, 2006; Parsons et al., 1999; Rogawski, 2004; Van Dam and De Deyn, 2006).”
BackgroundJoo, I.-S., Hwang, D.-H., Seok, J. I., Shin, S.-K., & Kim, S. U. (2007) · Journal of Clinical Neurology · doi:10.3988/jcn.2007.3.4.181 · Cited by 45
“– have a final common pathway of neuronal injury as a result of glutamate receptor overstimulation, especially of the NMDA subtype.(25) Therefore, memantine might be a good candidate treatment for alleviating excitotoxicity associated with several neurodegenerative diseases.”
BackgroundWang, J., Guo, Z., Fu, Y., Wu, Z., Huang, C., Zheng, C., Shar, P. A., Wang, Z., Xiao, W., & Wang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw018 · Cited by 49
Pérez-Areales, F. J., Turcu, A. L., Barniol-Xicota, M., Pont, C., Pivetta, D., Espargaró, A., Bartolini, M., De Simone, A., Andrisano, V., Pérez, B., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.051 · Cited by 38
“Despite some evidence of disease-modifying effects by the currently approved anti-Alzheimer drugs [2-7], they are regarded and used as symptomatic drugs.”
Amidfar, M., Réus, G. Z., Quevedo, J., & Kim, Y.-K. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.023 · Cited by 43
Garzón, J., Herrero-Labrador, R., Rodríguez-Muñoz, M., Shah, R. M., Vicente‐Sánchez, A., Wagner, C. R., & Sánchez‐Blázquez, P. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.022 · Cited by 43
Comer, S. D., & Sullivan, M. A. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0775-2 · Cited by 43
“Memantine is a safe and effective medication (Mobius 2003) that appears to selectively activate the NMDA subtype of glutamate receptors at oral doses between 5 and 30 mg (Kornhuber et al. 1994; Kornhuber and Quack 1995; Lipton 2006; Parsons et al. 2000).”
BackgroundKapus, G. L., Gacsályi, I., Végh, M., Kompagne, H., Hegedűs, E., Leveleki, C., Hársing, L. G., Barkóczy, J., Bilkei‐Gorzó, A., & Lévay, G. I. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1121-z · Cited by 43
“For instance, indirect stimulation of the GABAA receptor by 1,4BDZs contrast to barbiturates (Haefely 1990) or uncompetitive blockade of NMDA receptors by memantine compared to competitive blockers of the receptor (Lipton 2006) can lead to a safer therapeutic approach.”
Background
Metadata
- Authors
- Lipton, S. A.
- Affiliations
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Corresponding author
- Lipton, Stuart A.
- ORCID
- Lipton, Stuart A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-01-20
- Volume
- 5
- Issue
- 2
- Pages
- 160-170
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1981238903
- Cited by
- 909
- References
- 98
- Citations by year
- 2026: 39 · 2025: 31 · 2024: 32 · 2023: 31 · 2022: 40 · 2021: 41 · 2020: 51 · 2019: 42 · 2018: 36 · 2017: 40 · 2016: 48 · 2015: 51 · 2014: 47 · 2013: 48 · 2012: 52
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- memantine, NMDA receptor antagonists, neuroprotection, Alzheimer's disease, dementia, glutamate excitotoxicity, calcium influx, free radicals, adverse drug reactions, clinical trial failure, NMDA receptor overactivation
- MeSH terms
- Animals, Humans, Memantine, Neurotoxins, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.